Antibiotics administration

ApprovedSmall molecule

TThe Central and Eastern European Gynecologic Oncology Group

Antibiotics administration is one of 37 small molecule programs targeting Premature rupture of membranes. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Premature Rupture of MembranesActive, not recruiting

PneumoniaActive, not recruiting

Premature Rupture of MembranesPhase 3

Active, not recruiting

PneumoniaApproved

Active, not recruiting

Competition

Competitive Landscape

547 competitors in Pneumonia

#DrugCompanyPhaseTrials

Antibiotics administration

TThe Central and Eastern European Gynecologic Oncology Group

Approved

1 2

Innohep

Alnylam Pharmaceuticals

Preclinical

1 3

Jakafi

Incyte

Preclinical

1 4

Neutrexin

WWest Japan Thoracic Oncology Group

Preclinical

12 5

Virazole

CConrado Roberto Hoffmann Filho

Preclinical

2 6

Prograf

VVeloxis Pharmaceuticals

Preclinical

1 7

Alka-Seltzer

AAbbott

Preclinical

1 8

Pepcid

KKenvue Brands

Preclinical

1 9

Aciphex

Akero Therapeutics

Preclinical

1 10

Tylenol

KKenvue Brands

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Recruiting

Premature Rupture of Membranes

NCT07107477

Clinical

Trials by Indication[1]

Pneumonia1 trial

Effect of Vitamin C on Length of Hospital Stay in Children With Severe Pneumonia

Recruiting·—·Phase 4·NCT07414693·90 enrolled

Premature rupture of membranes1 trial

TAILORED Therapeutic Regime in Patients With Preterm Premature Rupture Of Membranes to Prolong Pregnancy, Improve Maternal and Neonatal Outcomes, and Reduce Antibiotic Burden

Recruiting·TThe Central and Eastern European Gynecologic Oncology Group·Phase 3·NCT07107477·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Antibiotics administration. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Antibiotics administration compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Antibiotics administration. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The Central and Eastern European Gynecologic Oncology Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: TThe Central and Eastern European Gynecologic Oncology Group

Antibiotics administration

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Pneumonia1 trial

Premature rupture of membranes1 trial

References

Drug Info

Quick Facts

Related News